Navigation Links
Additional Results From Phase 3 Trial Of IVIG In Alzheimer's Reported At Alzheimer's Association International Conference
Date:7/16/2013

BOSTON, July 16, 2013 /PRNewswire-USNewswire/ -- Additional analyses from a negative Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in people with mild to moderate Alzheimer's disease were reported today at the Alzheimer's Association International Conference® 2013 (AAIC® 2013) in Boston.

"We learn more about Alzheimer's disease from every study," said Maria Carrillo, Ph.D., Alzheimer's Association vice president of Medical and Scientific Relations. "Even negative trials provide critical information to the research community for application in future studies to help us find better treatments, which are so desperately needed."

In May 2013, Baxter International announced topline results of the first Phase 3 clinical trial of IVIG as an add-on to established therapy in people with mild to moderate Alzheimer's disease, known as the Gammaglobulin Alzheimer's Partnership (GAP) Study. The drug did not meet either of its primary endpoints.

"These results show us exactly why drugs, in particular those that are approved for one disease that are being tested for another, must go through the very thorough FDA approval process," said Mary Sano, Ph.D., Director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine, Bronx, NY, and a member of the executive committee for the GAP Study. "The FDA process protects people from misguidedly using drugs that are not effective and may be very costly."

Dr. Sano is a member of the Alzheimer's Association Medical and Scientific Advisory Council.

Updated Results from the GAP Phase 3 Trial of IVIG in Mild to Moderate Alzheimer's

In their topline announcement in May 2013, the GAP Study researchers reported that the results were negative on the main outcome measures, which were two well-established tests of cogniti
'/>"/>

SOURCE Alzheimer's Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. 14 Additional Hospitals Select CareFusion Pyxis ES Platform To Improve Medication Management Efficiency, Safety
2. MediScripts and The Jed Foundation Team Up to Offer Physicians Additional Resources to Support Emotional Health of College-Age Students
3. C&J Industries Announces Additional Expansion
4. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
5. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
6. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
7. Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
10. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
11. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/28/2015)... FRANCISCO , August 28, 2015 ... expected to reach USD 49.12 billion by 2020, growing ... according to a new report by Grand View Research, ... estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of chronic ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the ... and good people, all for a good cause. In its second year, the “Music ... more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to ...
(Date:8/28/2015)... ... 28, 2015 , ... Healthpointe clinics throughout Southern California ... diving. The act of recreational diving exposes the body to extreme changes ... vital that all recreational and professional divers undergo regular comprehensive scuba physicals. Healthpointe’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug status ... any time soon, according to educational website Surviving Mesothelioma. Click here to read ... designation for mesothelioma last week from the FDA, will now head into Phase I ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... is pleased to welcome TJS Insurance Group as its newest Partner Firm. Founded ... guides them and keeps them focused on their goals. Within the past 10 ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known ... Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full clinic ... has been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... savings comes an extra,hour of sleep, but how ... to the daily cup of coffee, early birds ... the Flower Promotion Organization at:, http://media.medialink.com/WebNR.aspx?story=34055 ) ... that study participants reported being happier and more ...
... Stryker Corporation,(NYSE: SYK ) announced today that it will participate in the ... 8:30 a.m. Mountain Standard Time Credit ... November 27, 2007 - 12:30 p.m. ... Care Conference New York, New York ...
... University Class Tests Benefits of Chewing Gum During Exam, ... can,be particularly stressful on college students as they struggle ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071101/AQTH193 ) "It,s common practice ... and pull all-nighters in preparation for exams," says Adrinda,Kelly, ...
... Centers, Inc.,("GNC" or the "Company"), announced today that it ... third quarter 2007 financial,results at 11 a.m. EST Thursday, ... the U.S., dial 1-888-895-5479, and,outside the U.S. dial 1-847-619-6250. ... webcast of the call will also be available,through the ...
... awards,Ashaway,s horse-assisted rehabilitative therapy with Premier Center Program ... ... Nov. 1 Turning Pointe,Therapeutic Riding has again been recognized ... the Handicapped Association (NARHA),the national standard bearer for therapeutic equine ...
... Kids,Indiana Action Fund launched an independent, direct ... supporting local elected officials who,have championed smoke-free ... - D) and Scott Keller (District 16 ... in passing Indianapolis, smoke-free,ordinance. The Indianapolis smoke-free ...
Cached Medicine News:Health News:Stryker to Present at Investor Conferences 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 3Health News:As Exams Loom, Students Find Hope in a 'Stick' 4Health News:Turning Pointe Therapeutic Riding Recognized for Excellence in Providing Equine-Assisted Therapies to People with Disabilities 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 3
10 mm angled blade with notches on sides and tip. Round knurled handle with polished finish....
1 mm wide by 33 mm long malleable blade. Flat serrated handle with polished finish....
Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Medicine Products: